Salbutamol oral - Merck

Drug Profile

Salbutamol oral - Merck

Alternative Names: Albuterol oral - Schering-Plough; Proventil; Proventil Repetabs; Proventil Syrup; Salbutamol oral - Schering-Plough; SCH 13949W oral - Schering-Plough

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Schering-Plough
  • Developer Key Pharmaceuticals; Merck & Co
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Small molecules; Tocolytics
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma
  • Discontinued Facioscapulohumeral muscular dystrophy

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 30 Jun 1998 Investigation in Facioscapulohumeral muscular dystrophy in USA (PO)
  • 30 Jun 1998 Launched for Asthma in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top